

April 11, 2023

The Honorable Dusty Johnson
U.S. House of Representatives
1714 Longworth House Office Building
Washington, D.C. 20515

The Honorable Abigail Spanberger
U.S. House of Representatives
562 Cannon House Office Building
Washington, D.C. 20515

Dear Representatives Johnson and Spanberger,

On behalf of Vizient, Inc., I am pleased to offer our endorsement for H.R. 2534, the Preserving Rules Ordered for the Entities Covered Through (PROTECT) 340B Act. The 340B Drug Pricing Program is a critical lifeline for hospitals across the country. Your important legislation would ensure that a providers' 340B status would not subject them to discriminatory reimbursement policies or other limitations that reduce the value derived from the 340B program.

Vizient is the nation's largest healthcare performance improvement company. Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 60% of the nation's acute care providers, which includes 97% of the nation's academic medical centers and more than 25% of ambulatory providers. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than \$130 billion in annual purchasing volume, to improve patient outcomes and lower costs. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

The PROTECT 340B Act would offer important protections to ensure that pharmacy benefit managers (PBMs) or health plans do not discriminate against 340B covered entities or their affiliated pharmacies. Specifically, the bill would prohibit PBMs and health plans from reducing reimbursement for covered drugs, or imposing burdensome terms and conditions or fees that differ from those applied to non-covered entities. The bill would also protect patient access to pharmacies of their choosing, and provides for a review to ensure that covered entities are not receiving duplicate discounts.

While this important legislation does not address all of the emerging challenges faced by eligible hospitals and other 340B providers, it offers essential protections and should be adopted. We are pleased to support this legislation and encourage its swift passage.

Thank you for your leadership in introducing this bill. Please do not hesitate to contact me at shoshana.krillow@vizientinc.com or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krillow
Senior Vice President, Public Policy & Government Relations